PHAT
NASDAQPhathom Pharmaceuticals Inc.
Price$6.92-0.39 (-5.34%)
01:45 PM07:45 PM
News · 26 weeks32+67%
2026-04-192026-10-11
Mix1390d
- Other5(38%)
- SEC Filings3(23%)
- Earnings2(15%)
- Insider2(15%)
- Analyst1(8%)
Latest news
25 items- PRPhathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026New analysis projects VOQUEZNA® (vonoprazan) to provide meaningful economic value and be cost-effective vs. proton pump inhibitors (PPIs) for adults with Erosive GERD, with potential cost savings at net price based on clinical healing and maintenance-of-healing data and fewer anticipated downstream complicationsAdditional Phathom-sponsored data highlight VOQUEZNA treatment effect across BMI subgroups in Non-Erosive GERD and real-world patient characteristicsVonoprazan was also the subject of 38 independent, investigator-initiated abstracts presented at ACG 2026, spanning GERD, H. pylori eradication, and other gastrointestinal conditions FLORHAM PARK, N.J., Oct. 12, 2026 (GLOBE NEWSWIRE) -
- INSIDERSEC Form 4 filed by Phathom Pharmaceuticals Inc.4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
- PRPhathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific MeetingThree scientific presentations will highlight new analyses of VOQUEZNA® (vonoprazan) in GERD, including real-world patient characteristics, efficacy across BMI subgroups, and cost-effectiveness in Erosive Esophagitis FLORHAM PARK, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting, being held October 9-14 in Nashville, Tennessee. Phathom will present three scientific posters featuring new data and analyses for VOQUEZNA®
- SECSEC Form 8-K filed by Phathom Pharmaceuticals Inc.8-K - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)
- PRPhathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERDInitiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 dataTopline results expected in the first quarter of 2028pHalcon-NERD-302, if successful, is intended to support a potential VOQUEZNA label expansion to include as-needed treatment of heartburn episodes in patients with Non-Erosive GERD, a treatment regimen of interest to patients for which proton pump inhibitors (PPIs) are not currently approved in the U.S. FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on the development and
- ANALYSTLeerink Partners initiated coverage on Phathom Pharmaceuticals with a new price targetLeerink Partners initiated coverage of Phathom Pharmaceuticals with a rating of Market Perform and set a new price target of $10.00
- INSIDERPrincipal Accounting Officer Breedlove Robert Charles covered exercise/tax liability with 460 shares, decreasing direct ownership by 0.77% to 59,465 units (SEC Form 4) to satisfy tax liability4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
- PRPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesFLORHAM PARK, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in September: 2026 Cantor Global Healthcare Conference in New York, NYDate: Wednesday, September 9, 2026Fireside Chat: 10:55 am EDTManagement to participate in one-on-one meetings throughout the conference H.C. Wainwright 28th Annual Global Investment Conference in New York, NYDate: Tuesday, September 15, 2026Fireside Chat: 3:30 pm EDTManageme
- SECSEC Form 10-Q filed by Phathom Pharmaceuticals Inc.10-Q - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)
- SECSEC Form 8-K filed by Phathom Pharmaceuticals Inc.8-K - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)
- PRPhathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update~1.7 million total VOQUEZNA® prescriptions filled to dateRecord Q2 2026 net revenues of $74.3 million, increased 88% vs. Q2 2025 and 27% vs. Q1 2026Q2 operating expenses of $63.1 million, reduced by 33% vs. Q2 2025Initiating Phase 3 clinical trial evaluating as-needed dosing of VOQUEZNA® in patients with Non-Erosive GERD (NERD)Updated full-year 2026 financial guidanceConference call and webcast today, July 30, 2026, at 8:00 a.m. EDT FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today reported financial results for t
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Phathom Pharmaceuticals Inc.SCHEDULE 13G/A - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)
- PRPhathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026FLORHAM PARK, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, July 30, 2026, to report its second quarter 2026 financial results and provide a business update. A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the call.
- INSIDERPrincipal Accounting Officer Breedlove Robert Charles covered exercise/tax liability with 1,555 shares, decreasing direct ownership by 3% to 59,925 units (SEC Form 4) to satisfy withholding tax4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
- SECSEC Form 8-K filed by Phathom Pharmaceuticals Inc.8-K - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)
- PRPhathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoETopline results for the double-blind 12-week treatment portion of the study are expected in Q4 of 2026 FLORHAM PARK, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced it has completed enrollment in its Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA® (vonoprazan) tablets as an investigational treatment for eosinophilic esophagitis (EoE) in adults. The study has enrolled 95 patients at 41 U.S. sites. Topli
- INSIDERDirector Parikh Asit received a gift of 28,000 shares and gifted 28,000 shares, decreasing direct ownership by 54% to 24,122 units (SEC Form 4)4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
- PRPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesFLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in May and June: Craig-Hallum 23rd Annual Institutional Investor Conference in Minneapolis, MNDate: Thursday, May 28, 2026 Management to participate in one-on-one meetings throughout the conference Jefferies Global Healthcare Conference in New York, NYDate: Wednesday, June 3, 2026Fireside Chat: 12:15 pm EDTManagement to participate in one-on-one
- INSIDERDirector Parikh Asit was granted 24,122 shares and exercised 17,500 shares at a strike of $4.95, increasing direct ownership by 396% to 52,122 units (SEC Form 4)4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
- INSIDERDirector Fields Heidi was granted 24,122 shares, increasing direct ownership by 80% to 54,122 units (SEC Form 4)4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
- INSIDERDirector Topper James N was granted 24,122 shares, increasing direct ownership by 57% to 66,718 units (SEC Form 4)4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
- INSIDERDirector Stenhouse Mark was granted 24,122 shares, increasing direct ownership by 80% to 54,122 units (SEC Form 4)4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
- INSIDERDirector Schroeder Theodore R was granted 24,122 shares, increasing direct ownership by 115% to 45,122 units (SEC Form 4)4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
- INSIDERDirector Cola Michael F was granted 24,122 shares, increasing direct ownership by 61% to 63,920 units (SEC Form 4)4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
- INSIDERDirector Karbe Frank was granted 24,122 shares, increasing direct ownership by 36% to 91,622 units (SEC Form 4)4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
PHAT FAQ
7 questionsWhat does Phathom Pharmaceuticals Inc. do?
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is...Where does PHAT stock trade?
Phathom Pharmaceuticals Inc. (PHAT) is listed on NASDAQ.What sector and industry is PHAT in?
Phathom Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Phathom Pharmaceuticals Inc. go public?
Phathom Pharmaceuticals Inc. (PHAT) completed its IPO in 2019.What are analysts saying about PHAT?
Phathom Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Market Perform with a $1000.00 price target on 2026-09-09. Recent price targets range from $1000.00 to $2800.00.What companies are similar to PHAT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PHAT side-by-side with any of them on Quantisnow.How can I track PHAT on Quantisnow?
Quantisnow aggregates Phathom Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PHAT to receive live email and push alerts on every new disclosure.